Newlimit
Latest round
- Series C
Last raised
- Jun 2026
Total raised
- $670M
Investors
- 16
About Newlimit
Based in the US, Newlimit, Inc. operates as a longevity pharma company that focuses on providing epigenetics programming and gene editing services.a. NewLimit operates as a biotechnology company that is working towards the radical extension of human health span using epigenetic reprogramming. In June 2026, Newlimit, Inc.1 billion post-money. The company is developing medicines to treat age-related diseases by reprogramming the epigenome, which is a new therapeutic mechanism for restoring regenerative potential in aged and diseased cells. The company utilizes machine learning models, pooled perturbation screening, and functional genomics to solve epigenetic aging biology and disease by going through experiments.
Who invested in Newlimit
16 investors across 4 rounds
See all investors in Newlimit
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Newlimit
Who invested in Newlimit?
Newlimit has 16 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Newlimit raised?
Newlimit has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Newlimit last raise money?
Newlimit's most recent round on record is a Series C, in Jun 2026.
What does Newlimit do?
Based in the US, Newlimit, Inc.
Where is Newlimit headquartered?
Newlimit is headquartered in South San Francisco, US.
Which VCs invest in companies like Newlimit?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Newlimit's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Newlimit? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.